Our products / APIs
Daptomycin - CMO
Daptomycin is a lipopeptide antibiotic active against gram-positive bacteria such as Staphylococcus aureus (including methicillin resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria in adult and pediatric patients and in the treatment of patients with Staphylococcus aureus (including MRSA-methicillin-resistant strains) bacteremia, as well as right-sided endocarditis in adults.
Application: Administered systemically as intravenous infusion or injection.
Downloadables
Product grades
Non-sterile
Packaging sizes
2 kg, alternative packaging size can be discussed with Sales Representative
Packaging material
Primary Packaging: The final product is packaged in 2-ply polyethylene bags under vacuum and heat-sealed.
Secondary Packaging: The product is then packaged in aluminium foil bag and heat-sealed.
Tertiary Packaging: The product is then placed in aluminium container and sealed.
Shelf life
3 years
Storage conditions
2 - 8°C
Compliance
No monograph for daptomycin in either Ph. Eur. or USP available
Manufacturing site
CMO for Xellia Pharmaceuticals ApS
Release site
Testing site: Xellia Pharmaceuticals Ltd., Budapest, Hungary
Release site: Xellia Pharmaceuticals Private Limited, Hyderabad, India
Site registered
US FDA approved
Regulatory documentation
US Drug Master File (DMF)
DMF also available in other selected countries
Want to hear more about our products?